In Wednesday’s Wall Street session, ProKidney Corp (NASDAQ:PROK) shares traded at $4.34, up 16.35% from the previous session.
PROK stock price is now 379.23% away from the 50-day moving average and 216.17% away from the 200-day moving average. The market capitalization of the company currently stands at $1.27B.
With the price target maintained at $1, BofA Securities recently Downgraded its rating from Neutral to Underperform for ProKidney Corp (NASDAQ: PROK). , while ‘Guggenheim’ rates the stock as ‘Buy’
In other news, Weber Darin J., Chief Regulatory Officer sold 103,480 shares of the company’s stock on Jul 08 ’25. The stock was sold for $312,510 at an average price of $3.02. Upon completion of the transaction, the Chief Regulatory Officer now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 08 ’25, Officer DARIN J WEBER bought 103,480 shares of the business’s stock. A total of $62,761 was incurred on buying the stock at an average price of $0.61. A total of 27.29% of the company’s stock is owned by insiders.
During the past 12 months, ProKidney Corp has had a low of $0.46 and a high of $4.92. The fifty day moving average price for PROK is $0.90562 and a two-hundred day moving average price translates $1.372685 for the stock.
The latest earnings results from ProKidney Corp (NASDAQ: PROK) was released for 2025-03-31.
